

Is Azasite in shortage in 2026? Get the latest update on Azasite availability, why supply is limited, pricing, and what patients can do right now.
If you've tried to fill a prescription for Azasite (Azithromycin ophthalmic solution 1%) recently and hit a wall, you're probably wondering: is there an actual Azasite shortage? The answer is nuanced — and in this article, we'll give you the full picture on what's going on with Azasite supply in 2026, why it's hard to find, what it costs, and what you can do about it.
As of late 2025, the FDA reported that Azasite is currently available. The product — Azithromycin ophthalmic solution 1%, 2.5 mL in 5 mL bottle (NDC 17478-307-03) — is being manufactured and distributed. So technically, there is no formal FDA-listed shortage of Azasite.
However, practical availability is a different story. Many patients report difficulty finding Azasite because:
So while supply exists, the distribution model creates an availability gap that feels like a shortage to many patients.
Several factors contribute to the limited availability of Azasite in 2026:
Azasite is not sold through standard retail pharmacy channels. It's distributed exclusively through EyeRx Direct at azasite.com. This means that even if your doctor prescribes it, your local CVS, Walgreens, or Walmart likely can't fill it.
There is no generic version of Azasite on the market. This means the entire supply comes from a single source, making it vulnerable to any production or distribution disruptions. For more on why this matters, see: Why is Azasite so hard to find?
The ongoing national shortage of erythromycin ophthalmic ointment has had a direct impact on Azasite demand. The FDA, CDC, and American Academy of Ophthalmology have recommended Azasite as an alternative for treating superficial ocular infections. This surge in prescriptions has strained an already narrow supply chain.
Azasite's manufacturing has changed hands multiple times — from InSite Vision to Inspire Pharmaceuticals, then to Akorn, and most recently to Sun Pharma following Akorn's bankruptcy in 2023. These transitions can disrupt production schedules and distribution networks.
Azasite is one of the more expensive antibiotic eye drops on the market:
Since there's no generic, patients pay brand-name prices regardless of insurance status. Some insurance plans cover Azasite, but many require prior authorization or step therapy (trying a cheaper alternative first). For detailed savings strategies, read: How to save money on Azasite.
While no new azithromycin ophthalmic product has entered the market, patients and providers have several proven alternatives:
These alternatives are effective against most bacteria causing conjunctivitis and are widely available at retail pharmacies. See our full comparison: Alternatives to Azasite.
If you need Azasite specifically, here's what to do:
For more strategies, read: How to find Azasite in stock near you.
While Azasite is not technically in an FDA-listed shortage in 2026, its specialty-only distribution, lack of generic, manufacturer changes, and spillover demand from the erythromycin shortage make it genuinely hard to find for many patients. The key is knowing where to look — the EyeRx Direct program remains the most reliable source — and being aware that effective, affordable alternatives exist.
If you're struggling to find or afford Azasite, use Medfinder to search availability and talk to your doctor about your options. Prompt treatment of bacterial conjunctivitis is important, so don't delay getting the care you need.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.